Benitec Biopharma

Company snapshot

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatme

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 13 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Benitec Biopharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Benitec Biopharma.

1. Jun 8, 2026 Clinical update

   BB-301: Dose escalation phase 1b cohort 1 — Phase 2

2. May 23, 2026 Clinical update

   BB-401 — Phase 2

3. Mar 19, 2024 Patent grant

   Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

4. Dec 27, 2022 Patent grant

   Reagents for treatment of hepatitis B virus (HBV) infection and use thereof

5. Feb 1, 2022 Patent grant

   Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

View all clinical trial activity →

• What is Benitec Biopharma?

  Benitec Biopharma is a biotech organization headquartered in Hayward, USA. It trades on NYSE under ticker BNTC. Primary therapeutic focus areas include Oculopharyngeal Muscular Dystrophy, Head and Neck Squamous Cell Carcinoma. NovaPharmaNews links 2 clinical program(s), 0 drug pr

• Is Benitec Biopharma publicly traded?

  Yes. Benitec Biopharma is listed with ticker BNTC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Benitec Biopharma develop or market?

  We link 3 drug profile(s) where Benitec Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/benitec-biopharma#company-drugs.

• What are the latest developments for Benitec Biopharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Benitec Biopharma focus on?

  Benitec Biopharma focuses on Oculopharyngeal Muscular Dystrophy, Head and Neck Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.